815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AAR reported fiscal third-quarter 2026 sales of $845.1 million, up 25% from a year earlier, and GAAP diluted earnings of $1.71 per share, compared with a loss of $0.25 per share in the prior-year quarter. The company raised its full-year fiscal 2026 total sales growth forecast to about 19% from approaching 17%, which supports the earnings outlook for shareholders, though GAAP profit included a $35.7 million bargain purchase gain.
Q3 sales were $845.1 million, up from $678.2 million; GAAP diluted EPS was $1.71 versus a loss of $0.25 a year earlier.
Adjusted diluted EPS was $1.25, up from $0.99; adjusted EBITDA was $102.1 million, up 26%.
Full-year FY2026 total sales growth guidance was raised to about 19% from approaching 17%; organic growth guidance to about 12% from approaching 11%.
Net leverage was 2.17x as of February 28, 2026, which the company says is within its 2.0x to 2.5x target range.
Worthington Enterprises reported fiscal 2026 third-quarter results for the period ended February 28, 2026, with net sales up 24% to $378.7 million and GAAP diluted EPS of $0.92, up from $0.79 a year earlier. The company also declared a quarterly dividend of $0.19 per share, unchanged from the prior quarter's level of $0.17 only in the sense that it is higher than last year's $0.17, and cash fell to $6.0 million after the LSI and Elgen acquisitions.
Net sales $378.7 million, up 24%; net earnings $45.1 million, up 15%; GAAP diluted EPS $0.92 versus $0.79
Adjusted diluted EPS $0.98 versus $0.91; adjusted net earnings $48.5 million, up 7%
Quarterly dividend of $0.19 per share, payable June 29, 2026, to shareholders of record on June 15, 2026
Cash and cash equivalents were $6.0 million at February 28, 2026, down $244.1 million from May 31, 2025, mainly due to the Elgen and LSI acquisitions
Paysign reported full-year 2025 revenue of $82.0 million, up 40.5%, and net income of $7.55 million, or $0.13 per diluted share, compared with $3.82 million, or $0.07, in 2024. The company also projected 2026 revenue of $106.5 million to $110.5 million and net income of $13.0 million to $16.0 million, with growth attributed mainly to its patient affordability business. Fourth-quarter 2025 net income of $1.36 million was down 0.8% from the prior-year quarter.
Full-year 2025 revenue was $82.0 million, up from $58.4 million in 2024.
Full-year 2025 net income was $7.55 million, or $0.13 per diluted share, versus $3.82 million, or $0.07, in 2024.
Q4 2025 net income was $1.36 million, down 0.8% from $1.37 million in Q4 2024.
2026 guidance: revenue of $106.5 million to $110.5 million and net income of $13.0 million to $16.0 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.